The OSDI was administered at baseline (pre-treatment) and during follow-up at 1 week, 1 month, and 3 months
In other words, micro-dosing of weight loss drugs is off-label (not approved by the FDA), unproven, and not supported by clinical trial data
"In fact, over 50 percent of current WeightWatchers members have expressed consideration of a compounded GLP-1 for their journey." Compound semaglutide typically works like name-brand GLP-1 injections but with a few differences
Tirzepatide & Semaglutide Tirzepatide and semaglutide often cause gastrointestinal side effects, which are typical for incretin mimetics
Patients who do not qualify under plan criteria, or whose plans exclude GLP-1 coverage entirely, may obtain medications outside traditional insurance channels, sometimes using manufacturer coupons or compounded formulations